Taysha Gene Therapies, Inc.
TSHA evidence brief
What we can confirm
- BioSniper Score:
- 7.0 / 10
- Market Cap:
- $1.79B
What it means
What to watch
Prepared research question
What matters most for TSHA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TSHA
Taysha Gene Therapies (TSHA) is a clinical-stage biotechnology company developing AAV-based gene therapies for central nervous system disorders, with its lead program TSHA-102 in Rett syndrome and no approved products or revenue to date.
Key risk: No approved products or revenue
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$1.79B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 clinical trials for Taysha Gene Therapies, Inc..
Taysha Gene Therapies (TSHA) is a clinical-stage biotechnology company developing AAV-based gene therapies for central nervous system disorders, with its lead program TSHA-102 in Rett syndrome and no approved products or revenue to date.
- Lead program TSHA-102 for Rett syndrome reported a 100% overall response rate in early trial data [news · 2026-08-13].
- Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials; topline data from 6-month interim analysis and FDA feedback on BLA submission pathway expected in 1H 2027 [news · 2026-08-11].
- Cash & equivalents of $455.4M as of 2026-06-30, with cash coverage into late 2028 [sec; news · 2026-08-13].
- Accumulated deficit of $800.3M as of June 30, 2026, with expectations of continued significant expenses and operating losses [sec_mda · as of 2026-08-11].
- No product candidates approved for sale and no revenue generated from product sales through June 30, 2026 [sec_mda · as of 2026-08-11].
What works
- TSHA-102 has shown a 100% overall response rate in early Rett syndrome trial data, indicating broad functional gains [news · 2026-08-13].
- The company has a strong cash position of $455.4M as of 2026-06-30, providing runway into late 2028 [sec; news · 2026-08-13].
- TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across trials (N=33) as of August 2026 [news · 2026-08-11].
What to weigh
- The company has no approved products and has never generated revenue from product sales [sec_mda · as of 2026-08-11].
- Accumulated deficit reached $800.3M as of June 30, 2026, with expectations of continued significant operating losses [sec_mda · as of 2026-08-11].
- The lead program is still in the clinical stage, and regulatory approval is uncertain and likely years away [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
TSHA-102 achieved 100% overall response rate in early Rett syndrome trial
“Taysha reports 100% overall response rate in early TSHA-102 Rett syndrome trial.”
News · August 13, 2026
No revenue from product sales
“We do not have any product candidates approved for sale and have not generated any revenue from product sales.”
SEC MD&A · August 11, 2026
Accumulated deficit as of June 30, 2026
“As of June 30, 2026, we had an accumulated deficit of $800.3 million.”
SEC MD&A · August 11, 2026
Catalyst timeline
- 2023-03-06 · Phase 3 Start (REVEAL pivotal trial) — Initiation of the Phase 1/2/3 study evaluating TSHA-102 in females with Rett syndrome.
- 2023-12-12 · Phase 2 Start (pediatric study) — Start of a multicenter, open-label, randomized dose-escalation and dose-expansion study in pediatric females with Rett syndrome.
- 2026-05-08 · Phase 3 Start (ASPIRE study) — Initiation of the ASPIRE study, an open-label trial evaluating safety, tolerability, and preliminary efficacy of TSHA-102.
Risks & what to watch (3)›
Key risks
- No approved products or revenue — Company has no approved products and has never generated product revenue; all operations funded by capital raises [sec_mda · as of 2026-08-11].
- Large accumulated deficit — Accumulated deficit of $800.3M as of June 30, 2026, with continued operating losses expected [sec_mda · as of 2026-08-11].
- Clinical-stage uncertainty — Lead program TSHA-102 is still in clinical trials; regulatory approval and commercial success are uncertain [sec_mda · as of 2026-08-11].
What to watch
- Topline data from the 6-month interim analysis of TSHA-102 pivotal trial expected in 1H 2027 [news · 2026-08-11].
- FDA feedback on the BLA submission pathway for TSHA-102 expected in 1H 2027 [news · 2026-08-11].
- Cash runway into late 2028 provides a buffer, but spending rates and potential need for additional financing should be monitored [news · 2026-08-13].
Sources: Catalysts · News · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Taysha Gene Therapies, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Taysha Gene Therapies, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.21 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Regulatory
Financials
Short Interest
as of Apr 28, 2026- % of float
- 13.8%
- Days to cover
- 12.8
- Shares short
- 38,915,976
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TSHA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Taysha Gene Therapies, Inc.?
Taysha Gene Therapies (TSHA) is a clinical-stage biotechnology company developing AAV-based gene therapies for central nervous system disorders, with its lead program TSHA-102 in Rett syndrome and no approved products or revenue to date.
Who is the CEO of Taysha Gene Therapies, Inc.?
Mr. Sean P. Nolan is the chief executive officer of Taysha Gene Therapies, Inc. (TSHA).
Where is Taysha Gene Therapies, Inc. headquartered?
Taysha Gene Therapies, Inc. (TSHA) is headquartered in Dallas, TX, United States.
What therapeutic areas does Taysha Gene Therapies, Inc. focus on?
Taysha Gene Therapies, Inc. develops therapies across Rare Disease, Gene Therapy, Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.